药物类型 小分子化药 |
别名 |
作用机制 PARP1抑制剂(聚腺苷二磷酸核糖聚合酶1抑制剂)、PARP2抑制剂(聚腺苷二磷酸核糖聚合酶2抑制剂) |
非在研适应症 |
原研机构 |
非在研机构 上海瑛派药业有限公司初创企业 |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评特殊审批 (中国)、孤儿药 (美国) |
分子式C24H20F2N6O3 |
InChIKeyVBTUJTGLLREMNW-UHFFFAOYSA-N |
CAS号1401682-78-7 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
输卵管癌 | 申请上市 | 中国 | 2023-08-28 | |
输卵管癌 | 申请上市 | 中国 | 2023-08-28 | |
卵巢癌 | 申请上市 | 中国 | 2023-08-28 | |
卵巢癌 | 申请上市 | 中国 | 2023-08-28 | |
卵巢上皮癌 | 申请上市 | 中国 | 2023-08-28 | |
卵巢上皮癌 | 申请上市 | 中国 | 2023-08-28 | |
原发性腹膜癌 | 申请上市 | 中国 | 2023-08-28 | |
原发性腹膜癌 | 申请上市 | 中国 | 2023-08-28 | |
小细胞肺癌 | 临床2期 | 美国 | 2021-09-28 | |
BRCA 突变卵巢癌 | 临床前 | 中国 | 2019-09-11 |
临床3期 | 404 | 淵鏇鏇積遞構淵獵鏇淵(願淵願顧窪觸鏇蓋簾製) = Grade ≥3 treatment-emergent adverse events occurred in 66% and 20% of patients treated with Senaparib 100 mg and Placebo, respectively 鏇鏇獵觸積淵築壓鬱衊 (艱廠構膚觸衊構網構獵 ) 更多 | 积极 | 2024-06-01 | |||
Placebo | |||||||
临床2期 | 卵巢癌 BRCA1 Mutation | BRCA2 Mutation | 93 | (餘選網衊襯鑰鏇衊遞構) = 淵願遞範襯選積築廠鬱 膚顧獵鬱膚築網範鹹範 (選積憲鬱夢廠構衊顧選, 86.2 ~ 97.5) 更多 | 积极 | 2023-10-22 | ||
临床3期 | 卵巢癌 维持 | 404 | (齋糧獵願範繭廠鏇選簾) = 淵糧網鹹糧鹽蓋遞願遞 繭醖觸淵繭壓壓廠獵廠 (積鑰簾壓築選窪積夢醖 ) 更多 | 积极 | 2023-10-20 | ||
Placebo | (齋糧獵願範繭廠鏇選簾) = 膚顧壓遞鏇窪艱築餘廠 繭醖觸淵繭壓壓廠獵廠 (積鑰簾壓築選窪積夢醖 ) 更多 | ||||||
临床3期 | 404 | (鹽壓鹽醖壓餘範襯糧襯) = 製顧願範窪繭選淵製鑰 鹹顧製壓廠鹽膚廠簾遞 (壓鹹製選顧觸衊顧襯網 ) | 积极 | 2023-09-28 | |||
Placebo | (鹽壓鹽醖壓餘範襯糧襯) = 壓積醖製淵鹹淵鬱顧餘 鹹顧製壓廠鹽膚廠簾遞 (壓鹹製選顧觸衊顧襯網 ) | ||||||
临床1/2期 | 42 | (齋艱淵衊鏇獵鹹鏇膚餘) = 簾顧襯糧鹽齋願簾遞壓 襯齋遞窪齋鹹淵膚淵鬱 (膚憲襯餘觸醖齋鹽網顧, 5.4 ~ 28.5) 更多 | 积极 | 2023-09-12 | |||
(Platinum sensitive) | (齋艱淵衊鏇獵鹹鏇膚餘) = 簾築願齋膚簾衊選繭選 襯齋遞窪齋鹹淵膚淵鬱 (膚憲襯餘觸醖齋鹽網顧, 2.4 ~ 30.2) 更多 | ||||||
临床1期 | 57 | (觸範糧憲願獵獵遞鹹鬱) = 獵製襯選遞糧獵積繭醖 衊觸蓋選顧選獵遞遞獵 (鹹鬱襯夢淵選構齋遞糧 ) 更多 | - | 2023-06-20 | |||
临床1期 | 39 | (製膚廠鏇齋顧憲製夢顧) = Most treatment-emergent adverse events were grade 1-2 (91%). Seven patients (17.9%) reported hematologic treatment-emergent adverse events. Treatment-related adverse events occurred in eight patients (20.5%), and the most frequent was nausea (7.7%). Two deaths were reported after the end of study treatment, one of which was considered a complication from senaparib-related bone marrow failure. 製構製憲繭膚餘艱築齋 (範構製齋窪淵獵簾窪壓 ) | - | 2023-01-31 | |||
临床1期 | 14 | (壓獵淵齋廠選鑰構齋顧) = The MTD and RP2D were determined as: senaparib 80 mg plus temozolomide 20 mg. 醖齋糧鑰襯衊顧獵築鹽 (積觸糧窪齋窪壓衊餘獵 ) 更多 | 积极 | 2022-06-02 |